All posts by Epic

PRED could be the Biggest Biotech Game-Changer on the Market as it plans to UPLIST to the NASDAQ!


Last Price: 4.60  |  Website  |  SEC Filings  |  Latest News

Today we venture back into the BioTech space with a play truly unlike anything we’ve ever seen before.

Rarely do you find a company of this esteem and Revenue Growth trading on the Penny Markets…the Pink Sheets no less!  But all that could be about to change….


Predictive Technology Group (PRED) aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories.

The focus here is on illnesses like endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products.

The company aims to use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively.

Now if that’s a moutful, well….we’ll explain later in this profile. But what you SHOULD know is that there’s BIG Money in this space…and PRED is already taking a nice chunk of it!

According to Allied Market Research, The Global Genetic Testing Market was valued at $7.5 BIL in 2017 and is projected to reach $17 BIL by 2025, growing at a rate of 11.3% from 2018 to 2025.

To say PRED has had a few good years lately is an absolute understatement!

This is a company that saw a 543% INCREASE IN REVENUES in 2018 over 2017 with $16.6 MIL!  But it gets better….

Looking at the first 3 reported Quarters of 2019, this company has already nearly DOUBLED 2018 Revenues and on pace to hit $40+ MIL!!

Bradley Robinson, CEO of Predictive Technology Group noted, “Revenue for the first nine months of fiscal 2019 exceeded $30 million, up 217% over the year-ago period, and we generated $3.1 million in cash flow from operations.

And if that’s not enough, respected Analysts, Zacks Small Cap Research recently gave PRED a Price Target of 8.00 – a 73% GAIN from the current price – while estimating strong Revenues for  years to come!

2018 Full Year Actual – $16.6M
2019 Full Year Estimate – $42M
2020 Full Year Estimate – $66.7M
2021 Full Year Estimate – $97.2M
Source: Zacks

So it’s no wonder why this company has already submitted their application to UPLIST to the NASDAQ Exchange!

No doubt the lucrative and groundbreaking prospects of PRED have attracted a who’s who of powerful executives from Pharma Giants like Pfizer and Quest Diagnostics to join the company’s Board.

In fact, former Senator Orrin Hatch, among the most respected and longest serving US Republican Senators has joined PRED’s Board as well!

“I’m excited to join Predictive and support its mission of delivering needed personalized care to millions of individuals through the commercialization of industry-leading breakthroughs in both genetics and cellular therapy,” said Senator Hatch.

“Predictive’s approach to precision medicine holds the promise of offering tremendous relief to those suffering from chronic ailments and debilitating pain. I have witnessed the pain and suffering of endometriosis at a personal level as it has impacted my family. I look forward to working toward achieving the company’s goals.”

Bullish Breakout charts are RARELY this perfect..

After making it’s initial ascent back in February around .87, PRED has slowly creeped up to hit highs of 6.91 with a few peaks and vallys along the way.

Each time PRED had retraced to it’s upwards trend line (yellow line), it BOUNCED back to greater highs!  See below…

The timing could not be better here as PRED just recently hit trend line support once again. Could another Blue Skies Rally be near?

Along with Zacks, on it’s side is, who currently gives PRED a “BUY” RATING!

So what’s all the fuss about with PRED?  Read on….

Predictive Technology Group, Inc.’s (PRED) mission is to revolutionize the care of patients through novel gene-based diagnostics and companion therapeutics.

PRED has emerged as a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through unique novel gene-based diagnostics, biotechnology treatments and companion therapeutics.

Both cellular therapy and genetic diagnostic tests are emerging areas in the health care space. For companies that can source, process and provide high quality medicines to the physicians who administer them, there is substantial opportunity. The same goes for genetic diagnostic tests that are developed and backed up by a genealogy database that can accelerate genetic discoveries.

Through its’ wholly-owned subsidiaries, Predictive Therapeutics and Predictive Biotech, the company focuses on four main clinical categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Human Cell and Tissue Products.

PRED’s ownership of a proprietary genealogy database with over 30 million individuals and greater than 300,000 DNA samples provides a valuable resource that can isolate genes that are implicated in disease and generate tests that are highly accurate.

In addition to Predictive Biotech’s efforts to advance regenerative medicine, PRED is committed to assisting women in overcoming the devastating consequences of endometriosis via appropriate early-stage diagnosis and subsequent treatment.

The company is currently collaborating on this with Thermo Fisher Diagnostics (NYSE: TMO) – a Billion Dollar NYSE traded company currently trading at just under $300./share!


Predictive Biotech – a leader in human cell and tissue products for use in regenerative medicine. A growing national network of clinics, health systems, researchers and physicians leverage the company’s four main placental-derived and Wharton’s jelly umbilical cord-derived products.

Human Tissue allograProducts include AmnioCyte, AmnioCyte Plus, PolyCyte, and CoreCyte. [Read More Here]

Predictive Laboratories – focuses on clinical and discovery work for human infertility and genetic conditions affecting women and children, such as endometriosis, scoliosis and degenerative disc disease.

Under this umbrella is ARTguide™ – the first, non-invasive, integrated test for endometriosis and genetic causes of infertility. Indicated for women, this test uses next-generation sequencers to examine critical genetic variables using a proprietary algorithm. ARTguide™ provides physicians with information that is essential when creating an accurate and personalized treatment plan.

Genetics play a major role in the body’s response to medications. PGxPLUS+™ helps healthcare providers prevent adverse drug reactions by providing genomic information that informs medication selection and dosing guidance.  It’s basically PERSONALIZED Medicine prescribed by YOU!

► CellSure – responsible for obtaining the source material for the cellular therapy segment which provides products derived from amniotic tissue and Wharton’s Jelly that are used by physicians in a variety of healing applications.

► Predictive Labs – created with the acquisition of Taueret Laboratories in March 2019. PL will launch genetic tests for endometriosis and degenerative disc disease in the coming quarters.

PRED’s revenues are generated exclusively in the self-pay market which allows for substantial flexibility in availability, pricing and distribution. The company is not required to conduct clinical trials for its cellular therapy products because they do not make efficacy claims.

However, for larger markets, such as the ones that exist for endometriosis and degenerative disc disease, an FDA-approved test provides the flexibility for broader acceptance and we anticipate PRED will pursue approval in these cases.

PRED’s commercialization strategy in cellular therapy boasts over 20 sales team members and over 75 distributors that will target the naturopathic physicians, chiropractors, orthopedists, anti-aging, and cosmetic medicine and other specialties that seek to treat pain without surgery.

PRED anticipates pursuing regulatory approval for specific indications in cellular therapy which will be guided by physicians treatment success with the current slate of products. The company is expected to pursue FDA clearance for diagnostic tests that are broadly used, such as the one intended for endometriosis.

PRED has identified a growth plan for each of its four segments.

Predictive Biotech will continue to grow Section 361 product, which does not make any efficacy claims while Predictive Therapeutics will pursue Section 351 products that require review and approval from the FDA.

CellSure will focus on procurement of tissue, optimizing cell yields and quality and offering storage services for new mothers. Predictive Laboratories, which was created and expanded through the acquisition of Taueret, will continue to develop and commercialize genetic diagnostic tests.

There’s no doubt that big developments are brewing for this exceptional BioTech company and it’s attracted everyone from big Pharma Executives to NYSE-traded companies to get involved!

As we said, RARELY do you find a company with such tremendous Revenue Growth, groundbreaking tech and products, and powerful BULLISH Chart on the Pink Sheets!

But the stars are aligning and PRED could now be destined for a NASDAQ Uplist which will bring a plethora of new eyes like investors and institutions to it’s stock!

But for right now, YOU still have the opportunity to check this breakthrough company out BEFORE this potentially happens!

Make sure you put PRED on your screen RIGHT NOW and Follow on Twitter for Updates + Play-by-Play!


We encourage all to read the SEC INVESTOR ALERT before reading our Newsletter.

COMPENSATION: has been compensated eighty thousand dollars cash via bank wire by a third party, Awareness Consulting Network LLC for a one day Predictive Technology Group Inc. marketing services contract. does not own any shares of PRED. does not investigate the background of any third party. The third party may have shares and may liquidate it, which may negatively affect the stock price. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. may purchase shares on the open market of any mentioned company following the dissemination of this email.

Sign up for Text Message Alerts

The  FASTEST WAY  to receive our Alerts!

Fill out the form to receive our text alerts or simply Text the word:  EPIC  to the number:  71441.

Mobile Number:     

Standard Message and Data Rates Apply.

At anytime you can reply to any text with the word ‘HELP‘ to
get more information or ‘STOP‘ to cancel your account.  Terms of Service | Privacy Policy

Mobile Number:  

Standard Message and Data Rates Apply.

At anytime you can reply to any text with the word ‘HELP‘ to
get more information or ‘STOP‘ to cancel your account.  Terms of Service | Privacy Policy


IPRU (Innovative Product Opportunities, Inc.) is our New Epic Pick!Last Trade: .0017  |  SEC Filings  |  Latest News

Begin your research at

Today we intend to close the month of March in a big way with what may be the most innovative Tech Sub-Pennies on the OTC markets today!

Touchscreen technology is no longer a “new thing”.  It’s everywhere from our smartphones and tablets to our laptop computers.  However, today’s alert is utilizing this technology in not only a unique and interactive way – but literally – in a BIG WAY. Introducing…IPRU!


IPRU has taken touch technology to the next level by successfully engaging consumers using much larger mediums such as floor screens, table tops and window displays.  The company currently claims resellers in 21 countries and names Disney, Sony, Guess and Mazda among some of their clients!

Sounds amazing right?  But equally amazing is IPRU’s incredibly BULLISH chart….

IPRU’s most recent Bullish run is nothing short of astonishing.

From Triple-Zero levels of .0002 in January to today’s price of .0017 – IPRU has certainly come a long way!

But could IPRU be ready to rise to the next level?

IPRU has now developed an impressive Bullish Trend which has held for over 2 months.

However, like kryponite, IPRU has failed to breach  .0017 after testing it over 12 times in the last month.

With all indicators now Bullish, we’ll be watching for a potential break of this key level to confirm a continuation to this trend.

On our side is who currently gives IPRU it’s top rating of STRONG BUY!  In addition, StockTA currently gives it a BULLISH overall rating!

IPRU (Innovative Product Opportunities, Inc.) is a research and product development firm specializing in interactive media products.  At the core is the company’s proprietary technology which turns ordinary surfaces into exciting self-motivated digital experiences.

IPRU brings static environments to life by enhancing existing infrastructure with interactive effects. The company can convert walls, floors, windows, and tables into a literal digital playground!

This allows IPRU to provide clients with a fresh new approach to delivering their messages and enhancing their brand through interactive multi-touch and even multi-user recognition – the more participants, the merrier!

But instead of trying to explain it, you can see it with your own eyes!  Click Play on the video below:

Did you see that?  IPRU has created video lighting for floors, walls, windows, displays, and more to react and animate to the user’s movements!  INCREDIBLE!

IPRO has absolutely taken touch to the next level.

Their core software, the heart of Imagin8, is a powerful and easy to use proprietary platform that allows it to simply track hand and body movement.

Think about all the concerts, nightclubs, broadway plays, retail stores, and  more that could use this technology!  The possibilities are ENDLESS!

In fact, I have personally seen this technology used at Muse concerts.  IPRU has already implemented it’s technology in a top Toronto nightclub that now has an interactive bartop and has tested it’s technology with a multi-platinum Grammy-award winning Artist!

IPRU is certainly not a company to simply rest on it’s laurels.
Earlier this month, IPRU announced a partnership with Lusens Inc. – a company specializing in many of the same technologies.  Check out Lusens’ amazing products, installations, and technologies HERE

Already this partnership appears to be paying off as the companies worked closely to deliver an Interactive Donor Recognition Wall to the Toronto Humane Society!

Amazing Technology, Growth, new partnerships, a Sub-Penny Pricetag, and a Bullish Chart….What’s not to love about IPRU?!

Make sure you put it on your screen RIGHT NOW and Follow on Twitter for all the Updates + Play-by-Play!

Good Trading,


GO VIP for a Limted Time Only!  Read More…

Please read our Full Disclaimer:

This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.  The paying party may own shares and may liquidate them during the promotional period.

PLEASE NOTE WELL: and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. EPICSTOCKPICKS.COM WILL NEVER ACCEPT FREE OR RESTRICTED TRADING SHARES IN ANY COMPANIES MENTIONED at EPICSTOCKPICKS.COM &/OR ANY OF OUR SOCIAL NETWORKING AND EMAIL ADVERTISING PLATFORMS.

You are reading this newsletter because you have subscribed via our Opt-In Signup form on our Website. If you have been subscribed by mistake, you may unsubscribe here.

Our website and newsletter are for entertainment purposes only. This newsletter is NOT a source of unbiased information.  Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Gains mentioned in our newsletter and on our website may be based on End of Day or intraday data. The disclaimer is to be read and fully understood before using our site, or joining our email list. Full disclaimer can be read at

We encourage all to read the SEC’s INVESTOR ALERT before reading our Newsletter.

Release of Liability: Through use of this email and/or website advertisement viewing or using you agree to hold, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by or an offer or solicitation to buy or sell any security.

COMPENSATION: has been compensated fifty-nine thousand dollars cash via bank wire by a third party, Cream Consulting Group, Inc. for a one day, Innovative Product Opportunities, Inc. advertising services contract. has been previously compensated twenty thousand dollars cash via bank wire by a third party, Microcap Innovations, LLC for a one day, Innovative Product Opportunities, Inc. advertising services contract which has expired. does not own any shares of IPRU. does not investigate the background of any third party. The third party may have shares and may liquidate it, which may negatively affect the stock price. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. may purchase shares on the open market of any mentioned company following the dissemination of this email. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is collected from public sources only such as the profiled company’s website, news releases, and corporate filings, but has not been verified in any way to ensure the publicly available information is correct. makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Further, has no advance knowledge of any future events of the profiled companies which includes, but is not limited to, news press releases, changes in corporate structure, or changes in share structure.

None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. is compliant with the Can Spam Act of 2003. does not offer such advice or analysis, and further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements.  Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks an uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.  Past Performance is based on the security’s previous day closing price and the high of day price during our promotional coverage.

In preparing this publication, has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. is not responsible for any claims made by the companies advertised herein, nor is responsible for any other promotional firm, its program or its structure.